Synlogic IncNASDAQ:SYBX
- LAST PRICE1.8400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 1.8400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SYBX |
|---|---|---|
| 09:32 ET | 110 | 1.86 |
| 09:36 ET | 100 | 1.8853 |
| 09:43 ET | 1648 | 1.9 |
| 09:48 ET | 100 | 1.86 |
| 09:57 ET | 7143 | 1.9 |
| 09:59 ET | 2684 | 1.9 |
| 10:06 ET | 6193 | 1.92 |
| 10:08 ET | 200 | 1.86 |
| 10:42 ET | 1075 | 1.875 |
| 12:48 ET | 400 | 1.89 |
| 01:35 ET | 129 | 1.79 |
| 01:57 ET | 200 | 1.84 |
| 02:04 ET | 221 | 1.84 |
| 02:58 ET | 100 | 1.84 |
| 03:59 ET | 100 | 1.84 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Synlogic Inc | 21.8M | -0.2x | --- |
Lumos Pharma Inc | 21.0M | -0.6x | --- |
Lipocine Inc | 28.0M | -1.6x | --- |
Dare Bioscience Inc | 28.2M | -0.9x | --- |
Singular Genomics Systems Inc | 29.2M | -0.3x | --- |
OncoCyte Corp | 20.7M | -0.8x | --- |
Company Information
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Contact Information
- Headquarters
- 301 Binney St Ste 402CAMBRIDGE, MA, United States 02142-1030
- Phone
- 617-401-9975
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Peter Barrett
- Chief Operating Officer, Head of Technical Operation
- Antoine Awad
- Director
- James Flynn
- Independent Director
- Michael Heffernan
- Independent Director
- Nick Leschly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.4M |
|---|---|
Revenue (TTM) | $3.4M |
Shares Outstanding | 11.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.02 |
EPS | $-11.41 |
Book Value | $4.64 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 6.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,636.34% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
